Analyst Price Targets — PYXS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 2, 2026 9:05 am | Jeffrey La Rosa | Leerink Partners | $7.00 | $2.85 | StreetInsider | Pyxis Oncology Inc. (PYXS) PT Lowered to $7 at Leerink |
| May 5, 2026 11:50 am | Robert Driscoll | Wedbush | $6.00 | $1.76 | TheFly | Wedbush bullish on Pyxis Oncology, initiates with an Outperform |
| December 18, 2025 7:36 pm | Leonid Timashev | RBC Capital | $5.00 | $1.73 | StreetInsider | Pyxis Oncology Inc. (PYXS) PT Lowered to $5 at RBC Capital |
| November 24, 2025 12:31 pm | Sudan Loganathan | Stephens | $8.00 | $4.80 | TheFly | Pyxis Oncology price target raised to $8 from $5 at Stephens |
| November 4, 2025 11:35 am | Bradley Canino | Guggenheim | $7.00 | $3.81 | StreetInsider | Pyxis Oncology Inc. (PYXS) PT Raised to $7 at Guggenheim |
| September 4, 2025 9:40 am | — | Guggenheim | $5.00 | $1.61 | TheFly | Pyxis Oncology initiated with a Buy at Guggenheim |
| August 16, 2024 6:46 am | Swayampakula Ramakanth | H.C. Wainwright | $7.00 | $3.52 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Pyxis Oncology Inc. (PYXS) |
| August 7, 2024 4:23 pm | Bradley Canino | Stifel Nicolaus | $10.00 | $3.13 | TheFly | Pyxis Oncology initiated with a Buy at Stifel |
| May 7, 2024 7:32 am | Farzin Haque | Jefferies | $10.00 | $4.31 | StreetInsider | Jefferies Assumes Pyxis Oncology Inc. (PYXS) at Buy |
Latest News for PYXS
Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap
Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused on patients treated at or below a dose cap Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose…
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences:
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment of Nelson Azoulay as Chief Business Officer.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PYXS.
U.S. House Trading
No House trades found for PYXS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.